SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50253RE Parkinson's. Article mentions "companies". Anybody else besidsemi_infinite -8/23/2018
50252Seems like it and low probability of personal injury law suits.semi_infinite 28/23/2018
50251China has 50% more trials than the US. Greater tolerance for risk? AshleyA.J. Mullen-8/23/2018
50250Neat chart. Thanks for the link. ArtArt Bechhoefer-8/23/2018
50249Car-T tracker the-scientist.comsemi_infinite -8/23/2018
50248Peter, You’re concluding that vitamin D deficiency is a “biomarker” for disease BulbaMan28/20/2018
50247At this point there have been a lot of studies adding D supplements to people wiBiomaven-8/19/2018
50246The article itself states: “Dr. Holick acknowledged financial ties with Quest anBulbaMan-8/19/2018
50245If I recall correctly he was a patient of Holick's, who does indeed recommenBiomaven-8/19/2018
50244An interesting article. I suspect anyone with MS friends or relatives' may Ian@SI28/19/2018
50243Longtime readers of this thread might recall the issues I had here with a devoutBiomaven-8/19/2018
50242Re ITI-214 (ITCI) in heart failure: Further discussion suggests that if one is htuck-8/18/2018
50241ITCI Currently I have no position, though I've sold puts on it a couple of tuck-8/17/2018
50240Thank you Peter and Rick, though I'm not sure I feel encouraged about your tquidditch-8/16/2018
50239AR-101 is, imo, very likely to succeed. Question is, will it work in the marketscaram(o)uche18/16/2018
50238While searching for the correct antibiotic (Peter is correct, get your butt to tscaram(o)uche28/16/2018
50237I think a consult with an ID (infectious disease) specialist is called for - thiBiomaven28/16/2018
50236Get better!Robohogs38/16/2018
50235biocqr, thanks so much: I had seen references to cedecea davisae, in the same Equidditch-8/16/2018
50234quidditch...not cedecea-neteri but found this > A rare bacteremia caused by biocqr18/16/2018
50233Speaking of anti-infectives, sometimes folks on this thread post personal items quidditch-8/16/2018
50232A technical distinction, there's the voting power of the shares, and the votmouton2928/14/2018
50231>>Synagis is a mab for one-time anti-infective use Not exactly accurate. Biomaven-8/13/2018
50230Synagis is a mab for one-time anti-infective use.DewDiligence_on_SI-8/13/2018
50229Interesting article. These questions are like those on polls - small tweaks in wBiomaven-8/13/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News